Open AccessComparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV
Author(s) -
Kathleen Squires,
Adriano Lazzarin,
José M. Gatell,
William G. Powderly,
Vadim Pokrovskiy,
Jean François Delfraissy,
Joseph G. Jemsek,
Antonio Rivero,
Willy Rozenbaum,
Shan Schrader,
Michael Sension,
Asda Vibhagool,
Alexandra Thiry,
Michael Giordano
Publication year - 2004
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200408150-00003
Subject(s) - atazanavir , efavirenz , lamivudine , zidovudine , medicine , ritonavir , pharmacology , viral load , gastroenterology , virology , antiretroviral therapy , human immunodeficiency virus (hiv) , viral disease , virus , hepatitis b virus
Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia.